Scalable Production of Multi‐Source Hybrid Biomimetic Exosomes Co‐Loaded with Therapeutic Plasmids for Treatment of High‐Altitude Pulmonary Edema
Advanced Healthcare Materials · 2026-05 · 15 (20)
DOI: 10.1002/adhm.202504014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 18.03.2026. Verfasst von Sujia Si und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Exosomes, Plasmids, Hypertension, Pulmonary, Altitude Sickness. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Exosomes show therapeutic promise but face limitations in simultaneous targeting and potency. While hybrid exosome strategies combining multiple cell components can address this, current methods rely on native exosome extraction and drug loading, suffering from low yield and encapsulation efficiency. We developed a biological origin‐based hybrid biomimetic exosome (BOB‐HBE) platform that synthetically assembles exosomes using parent cell‐derived components through a water/oil/water emulsion method, overcoming production bottlenecks. For high‐altitude pulmonary edema (HAPE) treatment, we engineered hybrid exosomes combining: (1) vascular endothelial cell membranes for lung targeting, (2) mesenchymal stem cell factors for regeneration, and (3) eNOS‐encoding plasmid DNA to restore nitric oxide signaling. The BOB‐HBE platform achieved >150‐fold higher production yield than natural exosome isolation while enhancing pulmonary endothelial specificity. In HAPE models, these hybrid exosomes demonstrated triple therapeutic effects: restoring NO bioavailability, inhibiting pathogenic HIF‐1α/TGF/Smad1/5 signaling, and preventing endothelial‐mesenchymal transition and vascular remodeling. Consequently, they significantly attenuated HAPE progression by addressing both molecular pathways and tissue‐level pathology. This study establishes a scalable platform for constructing multifunctional exosome mimetics that maintain native exosome advantages while solving key production challenges. The cell‐origin‐informed design strategy offers a versatile approach for targeted therapy in pulmonary and vascular disorders, with potential clinical translation advantages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Xuzhou Medical University, Xuzhou, China.
- Huaihai Hospital Affiliated to Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Liqun Jiang
Zitieren
APA
Si, S., Wang, H., Xu, Y., Wang, J., Sun, L., Zhang, L., Zeng, M., Zhao, J., Yu, H., Zhao, R., & Jiang, L. (2026). Scalable Production of Multi‐Source Hybrid Biomimetic Exosomes Co‐Loaded with Therapeutic Plasmids for Treatment of High‐Altitude Pulmonary Edema. Advanced Healthcare Materials, 15(20). https://doi.org/10.1002/adhm.202504014
Vancouver
Si S, Wang H, Xu Y, Wang J, Sun L, Zhang L, et al. Scalable Production of Multi‐Source Hybrid Biomimetic Exosomes Co‐Loaded with Therapeutic Plasmids for Treatment of High‐Altitude Pulmonary Edema. Advanced Healthcare Materials. 2026;15(20). doi:10.1002/adhm.202504014
BibTeX
@article{Si2026,
author = {Si, Sujia and Wang, Hong and Xu, Ya and Wang, Jian and Sun, Ling and Zhang, Lu and Zeng, Mengjun and Zhao, Jianling and Yu, Hairong and Zhao, Riguang and Jiang, Liqun},
title = {Scalable Production of Multi‐Source Hybrid Biomimetic Exosomes Co‐Loaded with Therapeutic Plasmids for Treatment of High‐Altitude Pulmonary Edema},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {20},
doi = {10.1002/adhm.202504014}
}
EUVIMED